Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Latest, Q2 2026
23,832
Period ended Jun 30, 2026
Change on a year earlier
+7.6%
22,140 in Q2 2025
History
59 quarters
Since Q4 2011
Sources
56
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Long-term debt, noncurrent ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 23,832 | +7.6% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 20,861 | -5.8% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 22,129 | -11.1% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 22,135 | +3.3% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 22,140 | +2.8% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 22,146 | +2.9% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 24,896 | +7.4% | Form 10-K (filed 2025-02-28) ↗ |
| Q3 2024 | Sep 30, 2024 | 21,437 | -7.6% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 21,540 | +1.6% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 21,527 | -6.2% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 23,189 | +1.0% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2023 | Sep 30, 2023 | 23,189 | +1.0% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 21,209 | -15.8% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 22,956 | -8.8% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 22,957 | -8.8% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2022 | Sep 30, 2022 | 22,953 | -8.8% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 25,195 | -9.7% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 25,183 | -9.8% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 25,179 | -12.1% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 25,175 | -9.4% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 27,914 | +32.3% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 27,907 | +26.3% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 28,645 | +29.7% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 27,792 | +25.8% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 21,103 | -12.4% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 22,098 | -8.2% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 22,094 | -10.1% | Form 10-K (filed 2020-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 22,090 | -10.1% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 24,084 | -7.6% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 24,080 | -9.3% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 24,574 | -20.2% | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2018 | Sep 30, 2018 | 24,570 | -10.7% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 26,062 | -0.9% | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 26,557 | +0.9% | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 30,795 | +16.9% | Form 10-K (filed 2018-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 27,515 | +4.3% | Form 10-Q (filed 2017-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 26,296 | +22.7% | Form 10-Q (filed 2017-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 26,321 | +24.9% | Form 10-Q (filed 2017-05-10) ↗ |
| Q4 2016 | Dec 31, 2016 | 26,346 | +25.0% | Form 10-K (filed 2017-02-27) ↗ |
| Q3 2016 | Sep 30, 2016 | 26,371 | +20.4% | Form 10-Q (filed 2016-11-07) ↗ |
| Q2 2016 | Jun 30, 2016 | 21,427 | +79.7% | Form 10-Q (filed 2016-08-05) ↗ |
| Q1 2016 | Mar 31, 2016 | 21,077 | +76.8% | Form 10-Q (filed 2016-05-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 21,073 | +76.8% | Form 10-Q (filed 2016-05-06) ↗ |
| Q3 2015 | Sep 30, 2015 | 21,894 | +176.0% | Form 10-Q (filed 2015-11-04) ↗ |
| Q2 2015 | Jun 30, 2015 | 11,922 | +50.3% | Form 10-Q (filed 2015-08-05) ↗ |
| Q1 2015 | Mar 31, 2015 | 11,921 | +50.3% | Form 10-Q (filed 2015-05-08) ↗ |
| Q4 2014 | Dec 31, 2014 | 11,921 | +202.6% | Form 10-K (filed 2015-02-25) ↗ |
| Q3 2014 | Sep 30, 2014 | 7,933 | +35.5% | SEC Filing ↗ |
| Q2 2014 | Jun 30, 2014 | 7,933 | +35.6% | SEC Filing ↗ |
| Q1 2014 | Mar 31, 2014 | 7,932 | +12.4% | SEC Filing ↗ |
| Q4 2013 | Dec 31, 2013 | 3,939 | -44.2% | Form 10-K (filed 2015-02-25) ↗ |
| Q3 2013 | Sep 30, 2013 | 5,856 | -16.8% | Form 10-Q (filed 2013-10-31) ↗ |
| Q2 2013 | Jun 30, 2013 | 5,850 | -17.9% | Form 10-Q (filed 2013-08-01) ↗ |
| Q1 2013 | Mar 31, 2013 | 7,055 | -12.7% | Form 10-Q (filed 2013-05-08) ↗ |
| Q4 2012 | Dec 31, 2012 | 7,055 | -7.2% | Form 10-K (filed 2013-02-27) ↗ |
| Q3 2012 | Sep 30, 2012 | 7,040 | – | Form 10-Q (filed 2012-11-06) ↗ |
| Q2 2012 | Jun 30, 2012 | 7,126 | – | Form 10-Q (filed 2012-08-01) ↗ |
| Q1 2012 | Mar 31, 2012 | 8,077 | – | Form 10-Q (filed 2012-05-04) ↗ |
| Q4 2011 | Dec 31, 2011 | 7,606 | – | Form 10-Q (filed 2012-05-04) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Long-term debt, noncurrent ($M) ($M), quarterly Q4 2011–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/fs_ltdebt
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.